FHTX Stock Analysis: Buy, Sell, or Hold?
FHTX - Foghorn Therapeutics Inc. Common Stock
$4.38
-0.13 (-2.78%)
▼
5d:
-14.05%
30d:
-22.98%
90d:
-18.98%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When FHTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: FHTX is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: FHTX is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: FHTX is currently trading at $4.38, which is considered oversold relative to its 30-day fair value range of $4.86 to $5.74.
Technical Outlook: Technically, FHTX is in a uptrend. The price is currently testing key support at $4.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FHTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.44 (+154.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FHTX is in a uptrend. The price is currently testing key support at $4.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FHTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.44 (+154.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.86 -
$5.74
Company Quality Score
35/100
(SELL)
Options IV Signal
25th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 25th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 154.3% below Wall St target ($11.44)
- WARNING: Recommendation downgraded due to -14.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$4.86 -
$5.74
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.61
(14.0%)
Support & Resistance Levels
Support Level
$4.39
Resistance Level
$5.36
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.94
Wall Street Target
$11.44
(+154.3%)
Revenue Growth (YoY)
223.8%
Profit Margin
-240.3%
Share & Embed Analysis
Last updated: March 30, 2026 3:32 PM ET
Data refreshes hourly during market hours. Next update: 4:32 PM
Data refreshes hourly during market hours. Next update: 4:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FHTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
